Curis Achieves Important Milestone in TakeAim CLL Clinical Trial for Advancing Cancer Treatment#USA#Lexington#Curis#emavusertib#TakeAim_CLL
Curis Achieves Important Milestone in TakeAim CLL Clinical Trial for Advancing Cancer Treatment
Curis, Inc. has successfully dosed the first five patients in its groundbreaking TakeAim CLL study with emavusertib, aimed at enhancing Chronic Lymphocytic Leukemia treatment.
third-news.com
July 30, 2026 at 12:28 PM
Curis Achieves Important Milestone in TakeAim CLL Clinical Trial for Advancing Cancer Treatment#USA#Lexington#Curis#emavusertib#TakeAim_CLL
Curis Inc. Begins Enrollment in TakeAim CLL Study with First Patient Consent#USA#Lexington#Curis#emavusertib#TakeAim_CLL
Curis Inc. Begins Enrollment in TakeAim CLL Study with First Patient Consent
Curis, Inc. announces milestone with the first six patient consents in its TakeAim CLL study, testing innovative treatment for chronic lymphocytic leukemia.
third-news.com
July 6, 2026 at 1:36 PM
Curis Inc. Begins Enrollment in TakeAim CLL Study with First Patient Consent#USA#Lexington#Curis#emavusertib#TakeAim_CLL